SBIR Award: Integrated BioTherapeutics
SBIR Award: Integrated BioTherapeutics to Create Therapeutic Multi-Specific Antibodies Using Technology from Zyngenia
Integrated Biotherapeutics (IBT) has been awarded a Phase I Small Business Innovative Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the NIH, entitled Multi-specific Antibody Therapy by Targeting S. aureus Toxins and Polysaccharides. The company will receive nearly $600,000 for work to take place over the next two years under principal investigator Dr. M. Javad Aman, President and CSO of IBT.
The pathogenicity of Staphylococcus aureus (S. aureus) is dependent on many virulence factors. Among them are cell surface proteins and polysaccharides, and secreted toxins that cause tissue damage, promote bacterial dissemination in distant organs, and enable the pathogen to evade the host innate immune response. Several vaccine and therapeutic candidates that target individual virulence factors have been tested with little success, highlighting the need for a multi-faceted approach. This grant is a collaborative effort between Zyngenia and IBT to address this need. Zyngenia is able to engineer a single molecule therapeutic that has the desired properties of a mAb but is able to simultaneously target several known mediators of a disease. By using IBT's S. aureus antibodies with Zyngenia's platform technology the collaboration aims to generate multispecific antibodies called Zybodies(TM). Zybodies will be constructed to target one cell-associated virulence factor along with two soluble toxins.
"Zyngenia is very excited to be working with IBT in the development of multi-specific antibody-based drugs for the treatment of antibiotic-resistant infections," said Dr. David Hilbert, Zyngenia's Chief Scientific Officer and principle investigator on the Subcontract. "IBT's expertise in bacterial pathogens complements our proprietary Zybody(TM) platform in a clinical area with great unmet medical need. "
"This approach could mitigate some of the unique challenges to treating Staph infections that the current standard of care of antibiotics does not address, namely the effect of bacterial toxins on the host", said Dr. Aman.
If successful, IBT would apply for a subsequent Phase II SBIR that would fund humanization and optimization of the Zybodies, expansion of molecular targets, and standard preclinical studies required for submission of an Investigational New Drug application to the FDA.